Metabolism

Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan

Retrieved on: 
Friday, April 5, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Clinical Trials, Immune system, Human, Notifiable disease, Therapy, Muscle atrophy, Multimedia, Metabolism, Sarcopenia, Facial muscles, DSM-IV codes, Cell, Inc., Vaccine

View the full release here: https://www.businesswire.com/news/home/20240405602477/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405602477/en/
    “Aging is a manifestation of immune decline.
  • This staggering statistic emphasizes the need for interventions that restore immune function to prevent the onset of such diseases.
  • By focusing on the prevention of immune dysregulation and the maintenance of immune health, Immunis aims to empower individuals to take charge of how they age.
  • Immunis aims to ignite a conversation on the profound benefits of nurturing the immune system for a transformative impact on muscle health and ultimately, human healthspan.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Immunis Publishes Research Showing Secretomes Improve Metabolism and Muscle While Reducing Fat in Aged Models

Retrieved on: 
Tuesday, March 19, 2024
Men, Other Health, General Health, Pharmaceutical, Consumer, Infectious Diseases, Fitness & Nutrition, Biotechnology, Women, Alternative Medicine, Seniors, Vitamins, Supplements, Health, Metabolism, Adipose tissue, Obesity, Facial muscles, Connective tissue, Blood, Immunotherapy, Inc., Weight gain, Ageing, Fracture, Research, Mouse, DSM-IV codes, Aging Cell, University, Hope, Human, Muscle atrophy, Sarcopenic obesity, Therapy, Hospital, Dietary supplement

The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.

Key Points: 
  • The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.
  • As we age, our metabolic health declines and commonly manifests as obesity, muscle atrophy, and reduced physical function.
  • Dr. Drummond’s independent research in aged mouse models shows that Immunis’ immunotherapy, IMMUNA, increases whole-body lean mass and reduces fat mass, while increasing muscle fiber area.
  • Muscle quality improved such that there was an increase in muscle ‘stem’ cells, enhanced collagen turnover, more blood vessels and decreased muscle fat.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
Monday, March 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.

Agilent Presents 2024 Darlene Solomon Award to University of Cambridge Researcher Joycelyn Tan

Retrieved on: 
Thursday, March 14, 2024
Software, Research, Hardware, Electronic Design Automation, Consumer Electronics, Consumer, Technology, University, Health Technology, Education, Science, Women, Health, Metabolism, Obesity, Environment, Travel, Fazakerley, Female, Systems biology, Wellcome, Lipidomics, National university, Mass spectrometry, Woman, Doctor of Philosophy, Agilent Technologies, Behavior, DSM-IV codes, Pharmaceutical industry

Agilent Technologies Inc. (NYSE: A) announced today that Joycelyn Tan, a Ph.D. student at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge , UK, has been awarded the 2024 Darlene Solomon Award .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) announced today that Joycelyn Tan, a Ph.D. student at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge , UK, has been awarded the 2024 Darlene Solomon Award .
  • “I am grateful to receive this award from Agilent and FeMS,” said Ms. Tan.
  • Additionally, she will have the opportunity to visit the Agilent Global Solutions Development Center in Singapore, where she will work alongside Agilent scientists.
  • The Darlene Solomon Award is co-sponsored by FeMS (Females in Mass Spectrometry) and Agilent Technologies.

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Metabolism, GSK plc, Pharmacy, GSK, Cornell University, Patient, Acquisition, Marker, University, Biology, MBA, Agilent Technologies, Research and development, Therapy, Takeda, Patient safety, TYK2, Vaccine, Human, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.
  • “We are honored to welcome Dr. Knobil to our Board of Directors as we embark on the next exciting chapter at Nimbus with plans to accelerate and expand our development programs in multiple therapeutic areas including oncology, immunology, and metabolism.
  • Dr. Knobil is currently a member of the Board of Directors at Marker Therapeutics (NASDAQ: MRKR) and Pliant Therapeutics (NASDAQ: PLRX).
  • “Nimbus has built a robust R&D organization that has demonstrated continued success in advancing promising discovery-stage science to product development.

AquaBliss Introduces Revolutionary Cold Water Shower Filters to Enhance Wellness

Retrieved on: 
Thursday, April 4, 2024
Credible, Inflammation, Chlorine, Health, Burn, Vitamin C, Cold, Immunity, Depression, Science, Filtration, Metabolism, Credibility, Common, News, Carbon, Mineral, Skin, Water, Mindfulness, Injury, Pain, Nail, Plumbing

WILMINGTON, Del., April 4, 2024 /PRNewswire/ -- Can the right choice in shower filter deliver health benefits? The answer, backed by both science and in real world feedback is a strong yes. AquaBliss, a leading provider of innovative water filtration solutions, understands this well. In exciting news, the company recently announced the launch of its AquaBliss shower filters designed to help deliver the benefits of cold water therapy. As the demand for holistic wellness solutions grows, AquaBliss is answering the call by offering filters that enhance the advantages of cold showers.

Key Points: 
  • High-quality shower filters may also be able to enhance benefits of Cold Water Therapy.
  • In exciting news, the company recently announced the launch of its AquaBliss shower filters designed to help deliver the benefits of cold water therapy.
  • As the demand for holistic wellness solutions grows, AquaBliss is answering the call by offering filters that enhance the advantages of cold showers.
  • By filtering out these harsh chemicals AquaBliss filters boost the positive qualities of cold showers while also delivering benefits that would not be possible without these filters.